| Post | Subject | | |
#228392
|
I don’t think one needs to listen to
|
jq1234
| 01/23/20 06:22:07 PM |
|
#228390
|
EPZM—FDA approves Tazverik (tazemetostat) for epithelioid sarcoma (metastatic
|
DewDiligence
| 01/23/20 06:05:14 PM |
|
#228358
|
MGNX: Marg OS benefit (difference) was weak, and
|
miljenko
| 01/22/20 11:54:26 PM |
|
#228356
|
On the surface these data look strong and
|
dewophile
| 01/22/20 04:41:54 PM |
|
#228401
|
Update data from RCC PIVOT2 (bem v bem+nivo)
|
miljenko
| 01/24/20 01:54:28 AM |
|
#228400
|
List price of EPZM’s Tazverik is $186K per
|
DewDiligence
| 01/23/20 08:03:52 PM |
|
#228399
|
NKTR—I never heard WL in any previous CC…he
|
DewDiligence
| 01/23/20 07:38:04 PM |
|
#228398
|
Pretty much. Current chronic HIV treatment isn’t cure.
|
jq1234
| 01/23/20 07:11:39 PM |
|
#228397
|
Got it—very clear now.
|
DewDiligence
| 01/23/20 07:08:28 PM |
|
#228396
|
Don’t read these two sentences as directly related.
|
jq1234
| 01/23/20 06:59:54 PM |
|
#228395
|
Re: Definition of “functional cure” …undetectable got to
|
DewDiligence
| 01/23/20 06:42:06 PM |
|
#228394
|
A little bit, undetectable got to last for
|
jq1234
| 01/23/20 06:37:28 PM |
|
#228393
|
NKTR—…you knew CMC issue as major already -
|
DewDiligence
| 01/23/20 06:34:50 PM |
|
#228392
|
I don’t think one needs to listen to
|
jq1234
| 01/23/20 06:22:07 PM |
|
#228391
|
The goal should be cure or functional cure…Are
|
DewDiligence
| 01/23/20 06:09:30 PM |
|
#228390
|
EPZM—FDA approves Tazverik (tazemetostat) for epithelioid sarcoma (metastatic
|
DewDiligence
| 01/23/20 06:05:14 PM |
|
#228389
|
The goal should be cure or functional cure,
|
jq1234
| 01/23/20 05:55:19 PM |
|
#228388
|
NKTR—I looked at past PIVOT-02 data presentations again,
|
DewDiligence
| 01/23/20 05:47:38 PM |
|
#228387
|
GILD is testing its oral PD-L1 inhibitor, GS-4224
|
DewDiligence
| 01/23/20 05:42:26 PM |
|
#228386
|
GILD is testing its oral PD-L1 inhibitor GS-4224
|
jq1234
| 01/23/20 05:13:22 PM |
|
#228384
|
{{Additionally, Forty Seven is evaluating magrolimab for the
|
vinmantoo
| 01/23/20 04:56:17 PM |
|
#228383
|
Re FTSV. Clinical data in patients
|
Whalatane
| 01/23/20 04:16:32 PM |
|
#228382
|
Never seen anything like Tril Today.
|
vinmantoo
| 01/23/20 04:13:41 PM |
|
#228381
|
Re: PD-(L)1 agents for HBV …I don't think
|
DewDiligence
| 01/23/20 03:51:20 PM |
|
#228380
|
The infection drives PD-L1 expression in hepatocytes [1].
|
jondoeuk
| 01/23/20 03:37:50 PM |
|
#228379
|
I was starting to think the SE profile
|
dewophile
| 01/23/20 03:02:32 PM |
|
#228378
|
Correct re ASMB soaring after dilution: #msg-152763587.
|
DewDiligence
| 01/23/20 03:01:02 PM |
|
#228377
|
Never seen anything like Tril Today.
|
dewophile
| 01/23/20 02:57:20 PM |
|
#228376
|
Never seen anything like Tril Today.
|
jbog
| 01/23/20 02:45:46 PM |
|
#228375
|
PS, I've had my share of Bad Trades also.
|
vinmantoo
| 01/23/20 02:06:21 PM |
|
#228374
|
lindtu,
They don't have the time or patience to
|
jbog
| 01/23/20 01:09:05 PM |
|
#228373
|
It’s fairly common for cash-poor biotechs to rise
|
DewDiligence
| 01/23/20 12:44:09 PM |
|
#228372
|
I don't understand why TRIL open mkt price
|
linhdtu
| 01/23/20 12:41:17 PM |
|
#228371
|
p.s. VIR’s CEO is George Scangos of BIIB/EXEL
|
DewDiligence
| 01/23/20 12:40:21 PM |
|
#228370
|
XENE announces pricing of public offering of common shares
|
bladerunner1717
| 01/23/20 12:18:21 PM |
|
#228369
|
Wow, Thats great, they spend it wisely.
|
vinmantoo
| 01/23/20 11:54:32 AM |
|
#228368
|
I would assume so. Supplying Cem.
|
miljenko
| 01/23/20 11:41:18 AM |
|
#228367
|
It is NIAID study, still waiting to start.So,
|
DewDiligence
| 01/23/20 11:16:29 AM |
|
#228366
|
They are not the only one. REGN with
|
miljenko
| 01/23/20 11:05:21 AM |
|
#228365
|
Chinese company tests PD-L1 agent in HBV(!?)…
|
DewDiligence
| 01/23/20 10:44:44 AM |
|
#228364
|
Folksy shareholder letter from RXMD CEO:
|
DewDiligence
| 01/23/20 10:35:55 AM |
|
#228363
|
$TRIL prices $101.7m offering at $2.75/share
|
jbog
| 01/23/20 08:45:11 AM |
|
#228362
|
$TRIL prices $101.7m offering at $2.75/share
$90m mkt
|
ronpopeil
| 01/23/20 08:31:06 AM |
|
#228361
|
Revance price target raised to $39 from $34
|
jbog
| 01/23/20 06:47:12 AM |
|
#228360
|
RVNC- Revance, Amphastar Named Top 2020 Specialty Pharmaceuticals
|
biotech_researcher
| 01/23/20 05:59:50 AM |
|
#228359
|
While I expect the normal short term dip
|
vinmantoo
| 01/23/20 12:22:00 AM |
|
#228358
|
MGNX: Marg OS benefit (difference) was weak, and
|
miljenko
| 01/22/20 11:54:26 PM |
|
#228357
|
TRIL offering
|
jbog
| 01/22/20 08:44:15 PM |
|
#228356
|
On the surface these data look strong and
|
dewophile
| 01/22/20 04:41:54 PM |
|
#228355
|
TRIL offering
|
ronpopeil
| 01/22/20 04:14:21 PM |
|
#228354
|
Dew agree its a long shot but note
|
rogerm
| 01/22/20 04:13:00 PM |
|
#228353
|
The data look marginal to me. If you
|
dewophile
| 01/22/20 03:16:03 PM |
|
#228352
|
NK. Anyone want to opine on todays price
|
Whalatane
| 01/22/20 03:16:02 PM |
|
#228351
|
AXSM—Would the FDA consider a AXS-05 NDA for
|
DewDiligence
| 01/22/20 02:52:02 PM |
| Post | Subject | | |